| Ytd | -41.49% | |
| 1y | -49.08% |
| Open | 224.74 | Prev Close | 224.53 | Low | 222.71 | High | 232.86 | Mkt Cap | 31.13B |
| Vol | 959.45K | Avg Vol | 1.78M | EPS | 6.15 | P/E | 37.83 | Forward P/E | 18.73 |
| Beta | 0.27 | Short Ratio | 4.19 | Inst. Own | 101.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 236.84 | 200-d Avg | 299.45 | 1yr Est | 371.12 |
ALNY News
Alnylam cut its full-year revenue guidance due to slower-than-expected sales for Amvuttra. Ionis exp
Alnylam Pharmaceuticals (NASDAQ: ALNY - Get Free Report) and Onconetix (NASDAQ: ONCO - Get Free Repo
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform a
The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQ
LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national
BENSALEM, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its invest
LOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its invest
Micron slides despite a record quarter as the 10-year yield nears 5.3% and oil tops $92, while Accen
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.0% on
JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight a
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi th
Alnylam Pharmaceuticals, Inc. shares have fallen 18% amid concerns over its ATTR-CM franchise follow
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance inn
Wall Street analysts are overwhelmingly bullish about Alnylam. The stock's attractive valuation and
Alnylam Pharmaceuticals (NASDAQ: ALNY - Get Free Report) and Tango Therapeutics (NASDAQ: TNGX - Get
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) has been assigned an average recommen
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:AL
Alnylam Pharmaceuticals (NASDAQ: ALNY) highlighted continued momentum for its AMVUTTRA treatment in
Alnylam Pharmaceuticals (NASDAQ: ALNY) outlined its strategy for advancing zilebesiran, an investiga
Alnylam Pharmaceuticals NASDAQ: ALNY highlighted continued momentum for its AMVUTTRA treatment in tr
Alnylam Pharmaceuticals NASDAQ: ALNY outlined its strategy for advancing zilebesiran, an investigati
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics fo
Analysts remain bullish about Alnylam despite its steep sell-off. The competitive landscape for Alny
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 6.49% on
Arizona State Retirement System grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: A
Concurrent Investment Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (N
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:AL
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.86% on
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced
The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are gree
Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Chec
BMO Capital analyst David Lebowitz initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) wi
Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-We
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.9% on
Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a B
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALN
Raymond James analyst Martin Auster upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Outperfor
Citigroup analyst Eric Joseph maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowe
Barclays analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight a
JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight a
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform a
Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-W
Oppenheimer analyst Kostas Biliouris maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outpe
Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-We
Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers
Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lo
Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighe